首页> 外文期刊>Journal of enzyme inhibition and medicinal chemistry. >Design and synthesis of novel pyrazolo[4,3- d ]pyrimidines as potential therapeutic agents for acute lung injury
【24h】

Design and synthesis of novel pyrazolo[4,3- d ]pyrimidines as potential therapeutic agents for acute lung injury

机译:新型吡唑并[4,3-d]嘧啶类药物的设计与合成作为潜在的急性肺损伤治疗药物

获取原文
获取外文期刊封面目录资料

摘要

Four series of total 35 new pyrazolo[4,3-d]pyrimidine compounds were designed, synthesized and evaluated for their inhibitory activity against LPS-induced NO production in RAW264.7 macrophages. Among them, compound 4e was found to be the most potent inhibitor, which decreased the production of cytokines in vitro, such as NO, IL-6 and TNF-α, with IC50 values of 2.64, 4.38 and 5.63?μM, respectively. Further studies showed that compound 4e inhibited cytokines secretion of macrophages through suppressing TLR4/p38 signaling pathway. Additionally, compound 4e showed in vivo anti-inflammatory activity in LPS-induced model of acute lung injury. These data suggested that compound 4e may be a promising lead structure for the treatment of ALI.
机译:设计,合成和评估了总共35种新的四个系列的吡唑并[4,3-d]嘧啶化合物对RAW264.7巨噬细胞中LPS诱导的NO产生的抑制活性。其中,化合物4e被认为是最有效的抑制剂,可降低体外NO,IL-6和TNF-α等细胞因子的产生,IC50值分别为2.64、4.38和5.63?μM。进一步的研究表明,化合物4e通过抑制TLR4 / p38信号通路抑制巨噬细胞的细胞因子分泌。此外,化合物4e在LPS诱导的急性肺损伤模型中显示出体内抗炎活性。这些数据表明,化合物4e可能是用于治疗ALI的有前途的先导结构。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号